APA (7th ed.) Citation

Moon, H., Zang, D. Y., Ryu, M., Seo, Y., Oh, B., Hwang, S., & Farrand, L. (2024). FDA regulatory considerations for oncology drug development. Pharmacology Research & Perspectives, 12(4), 1. https://doi.org/10.1002/prp2.1254

Chicago Style (17th ed.) Citation

Moon, Hanlim, Dae Young Zang, Min‐Hee Ryu, YeonSook Seo, Bitna Oh, Sunjin Hwang, and Lee Farrand. "FDA Regulatory Considerations for Oncology Drug Development." Pharmacology Research & Perspectives 12, no. 4 (2024): 1. https://doi.org/10.1002/prp2.1254.

MLA (9th ed.) Citation

Moon, Hanlim, et al. "FDA Regulatory Considerations for Oncology Drug Development." Pharmacology Research & Perspectives, vol. 12, no. 4, 2024, p. 1, https://doi.org/10.1002/prp2.1254.